Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Echinococcus multilocularis | EGFP:Bcl2 fusion protein | 0.0453 | 0.5 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0453 | 0.5 | 0.5 |
Schistosoma mansoni | hypothetical protein | 0.0453 | 0.5 | 0.5 |
Echinococcus granulosus | Bcl 2 ous antagonist:killer | 0.0453 | 0.5 | 0.5 |
Echinococcus granulosus | EGFP:Bcl2 fusion protein | 0.0453 | 0.5 | 0.5 |
Echinococcus multilocularis | Bcl 2 ous antagonist:killer | 0.0453 | 0.5 | 0.5 |
Schistosoma mansoni | hypothetical protein | 0.0453 | 0.5 | 0.5 |
Loa Loa (eye worm) | apoptosis regulator protein | 0.0453 | 0.5 | 0.5 |
Schistosoma mansoni | apoptosis regulator bax | 0.0453 | 0.5 | 0.5 |
Schistosoma mansoni | bcl-2 homologous antagonist/killer (bak) | 0.0453 | 0.5 | 0.5 |
Schistosoma mansoni | hypothetical protein | 0.0453 | 0.5 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Activity (functional) | = 30 mg kg-1 | Anticonvulsant activity in ip dosed CF1 albino mouse assessed as minimum effective dose after 0.5 hrs by MES screen test | ChEMBL. | 17826870 |
Activity (functional) | = 30 mg kg-1 | Anticonvulsant activity in ip dosed CF1 albino mouse assessed as minimum effective dose after 4 hrs by MES screen test | ChEMBL. | 17826870 |
Activity (functional) | = 30 mg kg-1 | Anticonvulsant activity in ip dosed CF1 albino mouse assessed as minimum effective dose after 0.5 hrs by scPTZ test | ChEMBL. | 17826870 |
Activity (functional) | = 30 mg kg-1 | Anticonvulsant activity in ip dosed CF1 albino mouse assessed as minimum effective dose after 4 hrs by scPTZ test | ChEMBL. | 17826870 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.